Display options
Cite
de Jong Y, van Oosterwijk JG, Kruisselbrink AB, et al. Targeting survivin as a potential new treatment for chondrosarcoma of bone. Oncogenesis. 2016;5:e222doi: 10.1038/oncsis.2016.33.
de Jong, Y., van Oosterwijk, J. G., Kruisselbrink, A. B., Briaire-de Bruijn, I. H., Agrogiannis, G., Baranski, Z., Cleven, A. H., Cleton-Jansen, A. M., van de Water, B., Danen, E. H., & Bovée, J. V. (2016). Targeting survivin as a potential new treatment for chondrosarcoma of bone. Oncogenesis, 5e222. https://doi.org/10.1038/oncsis.2016.33
de Jong, Y, et al. "Targeting survivin as a potential new treatment for chondrosarcoma of bone." Oncogenesis vol. 5 (2016): e222. doi: https://doi.org/10.1038/oncsis.2016.33
de Jong Y, van Oosterwijk JG, Kruisselbrink AB, Briaire-de Bruijn IH, Agrogiannis G, Baranski Z, Cleven AH, Cleton-Jansen AM, van de Water B, Danen EH, Bovée JV. Targeting survivin as a potential new treatment for chondrosarcoma of bone. Oncogenesis. 2016 May 09;5:e222. doi: 10.1038/oncsis.2016.33. PMID: 27159675; PMCID: PMC4945750.
Copy Download .nbib Format: NLM
Share it on

Oncogenesis. 2016 May 09;5:e222. doi: 10.1038/oncsis.2016.33.

Targeting survivin as a potential new treatment for chondrosarcoma of bone.

Oncogenesis

Y de Jong, J G van Oosterwijk, A B Kruisselbrink, I H Briaire-de Bruijn, G Agrogiannis, Z Baranski, A H G Cleven, A-M Cleton-Jansen, B van de Water, E H J Danen, J V M G Bovée

Affiliations

  1. Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  2. First Department of Pathology, Department of Clinical-laboratory Studies, Athens University Medical School, Athens, Greece.
  3. Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.

PMID: 27159675 PMCID: PMC4945750 DOI: 10.1038/oncsis.2016.33

Abstract

Chondrosarcomas are malignant cartilage-forming bone tumors, which are intrinsically resistant to chemo- and radiotherapy, leaving surgical removal as the only curative treatment option. Therefore, our aim was to identify genes involved in chondrosarcoma cell survival that could serve as a target for therapy. siRNA screening for 51 apoptosis-related genes in JJ012 chondrosarcoma cells identified BIRC5, encoding survivin, as essential for chondrosarcoma survival. Using immunohistochemistry, nuclear as well as cytoplasmic survivin expression was analyzed in 207 chondrosarcomas of different subtypes. Nuclear survivin has been implicated in cell-cycle regulation while cytoplasmic localization is important for its anti-apoptotic function. RT-PCR was performed to determine expression of the most common survivin isoforms. Sensitivity to YM155, a survivin inhibitor currently in phase I/II clinical trial for other tumors, was examined in 10 chondrosarcoma cell lines using viability assay, apoptosis assay and cell-cycle analysis. Survivin expression was found in all chondrosarcoma patient samples. Higher expression of nuclear and cytoplasmic survivin was observed with increasing histological grade in central chondrosarcomas. Inhibition of survivin using YM155 showed that especially TP53 mutant cell lines were sensitive, but no caspase 3/7 or PARP cleavage was observed. Rather, YM155 treatment resulted in a block in S phase in two out of three chondrosarcoma cell lines, indicating that survivin is more involved in cell-cycle regulation than in apoptosis. Thus, survivin is important for chondrosarcoma survival and chondrosarcoma patients might benefit from survivin inhibition using YM155, for which TP53 mutational status can serve as a predictive biomarker.

References

  1. Cancer Res. 2007 Sep 1;67(17):8014-21 - PubMed
  2. Med Oncol. 2015 Jan;32(1):377 - PubMed
  3. Drug Discov Today. 2015 May;20(5):578-87 - PubMed
  4. BMC Cancer. 2012 Aug 28;12 :375 - PubMed
  5. Nat Rev Cancer. 2008 Jan;8(1):61-70 - PubMed
  6. Int J Biochem Mol Biol. 2012;3(2):179-97 - PubMed
  7. Mol Cancer Ther. 2006 May;5(5):1087-98 - PubMed
  8. Cancer Res. 2009 Aug 1;69(15):6216-22 - PubMed
  9. J Pathol. 2015 Jul;236(3):348-59 - PubMed
  10. Semin Cell Dev Biol. 2015 Mar;39:91-6 - PubMed
  11. BMC Cancer. 2011 Apr 02;11:120 - PubMed
  12. Eur J Cancer. 2015 Feb;51(3):374-81 - PubMed
  13. J Cell Mol Med. 2009 Sep;13(9A):2843-52 - PubMed
  14. Eur J Surg Oncol. 2003 May;29(4):379-82 - PubMed
  15. Cell. 2012 Nov 21;151(5):937-50 - PubMed
  16. Oncologist. 2008 Mar;13(3):320-9 - PubMed
  17. Am J Pathol. 2013 Apr;182(4):1347-56 - PubMed
  18. Cancer Lett. 2013 Oct 10;339(2):167-74 - PubMed
  19. Clin Orthop Relat Res. 2000 Jul;(376):291-303 - PubMed
  20. Nature. 2011 Aug 03;478(7370):524-8 - PubMed
  21. World J Gastroenterol. 2011 Mar 28;17(12):1614-21 - PubMed
  22. Oncogene. 2002 Apr 18;21(17):2613-22 - PubMed
  23. Oncogene. 2015 Jul;34(29):3770-9 - PubMed
  24. Nature. 1998 Dec 10;396(6711):580-4 - PubMed
  25. Cancer Res. 2007 Jul 1;67(13):5999-6002 - PubMed
  26. Clin Cancer Res. 2013 Jul 15;19(14):3796-807 - PubMed
  27. Sci Transl Med. 2012 May 9;4(133):133ra56 - PubMed
  28. Genes Chromosomes Cancer. 2010 Jan;49(1):40-51 - PubMed
  29. J Pathol. 2006 Aug;209(4):501-11 - PubMed
  30. Diagn Pathol. 2008 Jul 15;3 Suppl 1:S25 - PubMed
  31. Br J Cancer. 2013 Sep 3;109 (5):1214-22 - PubMed
  32. Cancer. 2008 Jun;112(11):2424-31 - PubMed
  33. PLoS One. 2012;7(6):e32458 - PubMed
  34. J Exp Clin Cancer Res. 2015 Apr 25;34:38 - PubMed
  35. Oncogene. 2005 Aug 4;24(33):5258-61 - PubMed
  36. Ann Oncol. 2012 Jun;23 (6):1617-26 - PubMed
  37. Mol Cell Proteomics. 2012 Jul;11(7):M111.013243 - PubMed
  38. Lancet. 2002 Mar 16;359(9310):943-5 - PubMed
  39. Cancer Sci. 2011 Mar;102(3):614-21 - PubMed
  40. Int J Cancer. 1998 Sep 11;77(6):854-9 - PubMed
  41. Virchows Arch. 2007 Sep;451(3):691-9 - PubMed
  42. Biochim Biophys Acta. 2014 Apr;1845(2):202-20 - PubMed
  43. Lab Invest. 2003 Jun;83(6):877-87 - PubMed
  44. Leukemia. 1994 Aug;8(8):1342-9 - PubMed
  45. Nature. 2006 May 4;441(7089):106-10 - PubMed
  46. Pathol Oncol Res. 2012 Oct;18(4):793-802 - PubMed

Publication Types